Celestamine* L

Quick links to important sections

Celestamine* L

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celestamine* L

Quick Facts

Property Description
Active ingredients Betamethasone Dipropionate, Loratadine
Form Tablet, Oral solution
Pharmacological class Corticosteroid-Antihistamine Combination
Common use Systemic relief of inflammatory allergic disorders
Origin Synthetic

What Type of Medicine is Celestamine* L? (Identity and Classification)

Celestamine* L is a fixed-dose combination product designed for systemic oral administration, classified pharmacologically as a Corticosteroid-Antihistamine Combination agent. This synthetic medication integrates two different therapeutic classes into a single unit, frequently available as a Tablet or an Oral solution. The formulation combines a highly potent synthetic glucocorticoid with a second-generation, non-sedating antihistamine, a design specifically intended to address the dual nature of inflammatory allergic conditions. This positioning is often utilized when patients require systemic treatment minimizing the sedation associated with older antihistamines.

Core Composition: The Role of Betamethasone and Loratadine

The medicine is composed of the active ingredients Betamethasone Dipropionate and Loratadine. Betamethasone Dipropionate is a synthetic glucocorticoid responsible for profound anti-inflammatory and immunosuppressive action. Loratadine belongs to the class of antihistamines that work by selectively blocking histamine H1 receptors. This pairing represents a specific therapeutic strategy: combining the potent inflammatory suppression of a corticosteroid with the targeted, non-sedating relief of a modern antihistamine. This specific dual mechanism is recognized in pharmacological contexts for its ability to address both the root inflammation and the acute allergic symptoms.

What is the General Purpose of This Combination? (Mechanism and Benefit)

The overall general purpose of Celestamine* L is to leverage a synergistic dual mechanism to achieve broad and efficient suppression of symptoms associated with inflammatory allergic conditions. The oral combination of loratadine and betamethasone is an option for reducing the symptoms of allergic rhinitis. This means the medicine is designed to help alleviate the discomfort caused by severe seasonal or chronic allergies where both inflammation and allergic symptoms are prominent. This combination is often considered for situations requiring the definitive anti-inflammatory power of a steroid alongside sustained, high-selectivity H1 blockade.

What side effects are possible with Celestamine* L?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of the medicine, based strictly on government regulatory documents.

Category Documented Characteristics
Adverse Reaction Scope Most commonly reported effects include sleepiness, insomnia, dull headache, nausea/vomiting, loss of appetite, diarrhea, gastric ulcer, malaise, moon face, and weight increase (Source 1.5).
System-Organ Classes Effects are listed across Nervous System (e.g., confusion, convulsion), Gastrointestinal (e.g., pancreatitis), Endocrine/Metabolic (e.g., secondary adrenocortical insufficiency, diabetes mellitus), and Musculoskeletal (e.g., osteoporosis, myopathy) systems (Source 1.5).
Serious Adverse Reactions Officially documented serious symptoms include acute adrenal insufficiency, peptic ulcer, pancreatitis, mental disorders (such as hallucination or depression), and risks for induced infection or aplastic anemia (Source 1.5).

Population-Specific Safety Considerations

The official labeling notes specific caution for individuals with pre-existing conditions such as angle-closure glaucoma, peptic ulcer, tuberculosis, high blood pressure, and diabetes mellitus (Source 1.5). The use of the medicine during pregnancy or breastfeeding requires consultation (Source 1.5).

Time- and Constraint-Related Safety Patterns

The label specifies that sudden discontinuation may cause secession symptoms (withdrawal effects), which include fever, headache, lassitude, muscle pain, and arthralgia (Source 1.5). Furthermore, the official restriction notes the potential for drowsiness or dizziness, and warns that alcohol may intensify the medicine's effects. Patients planning to receive a vaccination should notify a healthcare professional (Source 1.5).

These safety domains structure the official risk profile by defining the adverse effects based on frequency and system involvement, establishing the full spectrum from common effects to rare, serious systemic constraints. The profile explicitly includes safety notes regarding special populations and time-related patterns, which collectively define the regulatory boundaries of the medicine's safety characteristics.

Overdose and Emergency Response

An overdose of the Betamethasone/Loratadine combination may present with manifestations related to both active ingredients, as described in regulatory documentation. Overdose of the corticosteroid component may lead to fluid and electrolyte disturbances, resulting in elevated blood pressure and potential imbalances such as increased potassium excretion. Overdose of the antihistamine component is primarily associated with Central Nervous System (CNS) effects, including somnolence, headache, and agitation.

Overdose carries the risk of severe or life-threatening outcomes, including cardiac arrhythmias, potential QT-interval prolongation, and serious neurological events such as seizures and coma. Children face an increased risk for CNS stimulation and seizures, while elderly patients may face an increased risk for cardiotoxicity and arrhythmias.

In the event of a suspected overdose, regulatory authorities mandate that immediate medical attention must be sought. It is required to contact a Poison Control Center or emergency services at once. Official management protocols focus on providing symptomatic and supportive treatment. Procedures described in regulatory labeling may include the use of activated charcoal to limit absorption and the implementation of continuous cardiac monitoring due to the risk of heart rhythm disturbances.

Therapeutic Uses of Celestamine* L

Addressing Severe Allergic Rhinitis and Inflammatory Congestion

This medication is commonly used to provide systemic symptomatic relief for patients experiencing severe perennial or acute exacerbations of allergic rhinitis. The combination is relevant when supportive symptom management is appropriate for severe perennial symptoms, including in school-aged children. The medicine is utilized for easing challenging manifestations that create noticeable physiological strain, such as persistent nasal congestion, excessive rhinorrhea (runny nose), sneezing, and ocular itching.


Symptomatic Control and Therapeutic Scope

Celestamine* L is applied across domains where additional symptomatic support is needed, particularly when symptoms that interfere with daily functioning have proven difficult to manage with standard monotherapy. Indications where this is used include the management of allergic rhinitis and certain symptoms of conditions associated with acute or disruptive episodes like Chronic Idiopathic Urticaria (hives). This use supports patients during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods.

“This approach is relevant when symptoms become momentarily overwhelming, requiring short-term symptomatic assistance.”

Quick Fact: Relief for Heightened Discomfort
Symptom Focus Congestion, sneezing, itching (nasal/ocular), hives
Use Context Acute exacerbations and severe perennial symptoms
Patient Benefit Assists with maintaining functional stability and comfort

Eligibility and Restrictions for Use

Eligibility for Celestamine* L: Official Regulatory Status

Official regulatory documents define the allowed and restricted populations for Celestamine* L (Betamethasone/Loratadine) based on its components. The rules center on absolute contraindications and mandatory cautions tied to the corticosteroid component.

Classification Population or Condition Status
Absolute Contraindication Systemic fungal infections; Hypersensitivity to any component; Newborn and premature infants; Patients on MAOI therapy Prohibited
Age-Group Eligibility Children 2 to under 6 years (oral solution); Children 6 years and older (tablet) Established Use
Conditional Use (Caution) Kidney disease; Liver disease; Hypertension; Congestive heart failure; Active peptic ulcer; Diabetes mellitus; Ocular herpes simplex; Older adults Use with Caution
Reproductive Status Pregnancy; Lactation (Breastfeeding) Restricted Use

Use is prohibited in any patient with a formal contraindication. For groups requiring caution (e.g., severe hepatic or renal impairment, specific cardiovascular conditions), use is restricted, requiring a careful weighing of necessity against risk, according to official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for this combination medicine (Betamethasone and Loratadine) outlines specific pharmacokinetic and pharmacodynamic interactions. Co-administration is formally contraindicated with live, attenuated vaccines and in patients with systemic fungal infections due to the immunosuppressive properties of the corticosteroid component.

Metabolic and Exposure Interactions

The clearance of the active ingredients can be altered by other medicines, resulting in a pharmacokinetic interaction. Strong metabolic enzyme inhibitors, such as Ketoconazole, Erythromycin, and Cimetidine, substantially increase the systemic plasma concentrations (exposure) of loratadine. Conversely, hepatic enzyme inducers, including Phenytoin and Rifampin, may enhance the metabolic clearance of betamethasone, potentially reducing its effect.

Pharmacodynamic and Additive Effects

Other interactions result in additive physiological effects rather than altered clearance:

Interacting Substance Category Official Interaction Outcome
Potassium-Depleting Agents (e.g., Diuretics) Increases the risk of hypokalemia (low potassium).
Antidiabetic Agents May increase blood glucose concentrations.
NSAIDs (e.g., Aspirin) Increases the risk of gastrointestinal side effects.

Non-Medicinal Interactions

Official documents note that administration with food increases the systemic bioavailability of loratadine. Additionally, while the exact interaction is unknown, consumption of alcohol may increase the risk of drowsiness.

Mechanism of Action

How Celestamine* L works

Celestamine* L modulates physiological responses through two distinct pharmacodynamic actions. The corticosteroid component, a synthetic glucocorticoid, crosses the cell membrane to bind to the intracellular glucocorticoid receptor (GR). The activated receptor-ligand complex then translocates to the nucleus where it regulates gene transcription. This process primarily involves transrepression, which inhibits the activity of key pro-inflammatory transcription factors, such as NF-kappaB and AP-1. By suppressing the synthesis of various pro-inflammatory mediators, including cytokines, chemokines, and prostaglandins, this component modulates the downstream cellular events that propagate inflammation.

The second component, an H1-receptor antagonist, exerts its effects at the cell surface. It functions as an inverse agonist at the histamine H1-receptor. This competitive binding prevents endogenous histamine from activating the H1-receptor. By stabilizing the inactive conformational state of the receptor, the antagonist blocks the histamine-mediated signal transduction cascade. This prevents specific downstream physiological changes typically induced by histamine, which include increased vascular permeability and contraction of smooth muscle. The dual action provides modulation of both inflammatory signaling and primary allergic mediator effects.

Dosage and Administration Information

How to Use Celestamine* L: Administration Guidelines

Celestamine* L, a fixed-dose combination, is used according to specific procedural instructions to ensure proper administration and patient safety. Administration involves specific parameters regarding route, dosing regimen, and handling.

Route and Dosage Forms

Item Description
Route of Administration The medicine is for Oral use, typically available as a Tablet or an Oral solution/Syrup.
Standard Dosing For adults, the typical dose is 1 to 2 tablets at a time. The dosage is individualized and is determined by a healthcare professional based on the patient's age and the severity of symptoms.

Administration and Scheduling Rules

  • Frequency: The medicine is generally taken multiple times per day, up to four times daily, as directed for symptomatic control.
  • Tablet Handling: Tablets are intended to be swallowed whole without being broken, crushed, or chewed.
  • Course Management: Due to the inclusion of a corticosteroid, the treatment duration is typically short-term. It is important not to stop taking the medicine suddenly; any decision to discontinue is made gradually and under medical supervision.
  • Missed Doses: If a dose is missed, the regular schedule is continued. Patients are advised not to take two doses simultaneously to compensate for a missed dose.

Population-Specific Use

Specific dosage modifications apply to certain groups. For pediatric patients, the dosage is adjusted based on the child's age and symptoms, often utilizing the oral solution/syrup form for accuracy. Additionally, for patients with severe hepatic impairment, a lower initial dosing frequency for the antihistamine component may be indicated.

Recent Clinical Evidence

Research evidence / Overview of Studies for Celestamine* L (Betamethasone/Loratadine)


Evidence for Use in Severe Allergic Rhinitis

Research has included conditions characterized by fluctuating or episodic manifestations, such as severe allergic rhinitis. Studies conducted during periods of increased symptom activity have primarily used short-term Randomized Controlled Trials (RCTs) in both adults experiencing severe symptoms and school-aged children with severe perennial allergic rhinitis. Researchers examined outcomes related to physical discomfort, such as overall symptom intensity and Nasal Obstruction Scores. Findings describe patterns observed in trials that used a single-agent antihistamine as a comparison group. The certainty of the evidence remains low due to certain study design limitations for measuring changes in specific symptoms, as some research reports indicated modest sample sizes for detecting differences.


Evidence for Use in Acute Urticaria (Hives)

The combination was studied in conditions associated with acute or disruptive episodes like moderate to severe acute urticaria. Research involved Comparative Prospective Studies, often with an open-label design. These studies explored outcomes describing acute changes, including the monitoring of decrease in urticarial lesions (hives count). Comparative evidence is lacking, and the follow-up durations were limited (typically 5 days). Data for symptom recurrence or any long-term outcomes remain insufficient.


Duration of Studies and What is Still Uncertain

The majority of published research examined short-term symptom changes, with clinical trials typically having very brief follow-up periods (5 to 7 days). Long-term effects are not fully established, and this constitutes a significant limitation in the overall research landscape. Research was primarily concentrated on adults and school-aged children. Data for certain groups, such as adolescents or older adults, remain insufficient. The evidence highlights what is known—and what is still uncertain—about this combination.

Key Studies & References

  1. Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Frequently Asked Questions (FAQ)

Common questions about Celestamine* L (FAQ)

Q: What is the main reason doctors prescribe Celestamine* L?

Official product information states the medicine is generally used in the treatment of inflammatory and allergic conditions. These uses typically include skin diseases such as hives (urticaria) and eczema, as well as allergic rhinitis.

Q: Can Celestamine* L be used for skin rashes or hives?

Official documentation indicates the medicine is used in the treatment of various skin diseases, including those associated with acute or disruptive episodes like hives (urticaria) and eczema. The scope of use is defined in the regulatory labeling.

Q: Do I need a prescription to get Celestamine* L?

Regulatory information suggests the medicine is classified as a prescription-only product. This is because the appropriate dosage is individualized and must be specifically determined by a healthcare professional based on the patient's age and the severity of symptoms.

Q: What if I miss a day of taking Celestamine* L?

If a dose is missed, official guidance states that patients should simply continue with their regular dosing schedule. It is explicitly stated that patients should not take two doses simultaneously to try and make up for the missed amount.

Q: Does Celestamine* L affect sleep patterns?

Official reports on side effects include issues related to sleep. The documented adverse reactions include both the potential for feeling sleepy (somnolence) and the potential for difficulty falling or staying asleep (insomnia).

Q: Is Celestamine* L similar to Claritin or Zyrtec?

Celestamine* L is a combination product that contains the ingredient loratadine, which is an H1-receptor antagonist. This means that loratadine belongs to the same class of allergy medicines as the active ingredients found in products like Claritin and Zyrtec.

Q: Can Celestamine* L be taken with vitamins or supplements?

Official warnings advise caution when combining this medication with any other products, which includes both over-the-counter medicines and dietary supplements. This is due to the potential for interactions.

Q: Is Celestamine* L safe to use if I have diabetes?

Official caution is noted for individuals with pre-existing conditions like diabetes mellitus. One component of the medicine may increase blood glucose concentrations, and any use should be discussed with a healthcare provider.

Q: What should I know about combining Celestamine* L with other allergy medicines?

Official documents caution about combining this medicine with other products, including other allergy medicines, as there is a potential for an altered medicinal effect. This requires professional awareness of the combination.

Q: Does Celestamine* L cause weight gain?

Official regulatory documents list 'weight increase' as one of the most commonly reported adverse reactions for the medicine. This information is based on observations from regulatory studies and safety reports.

Q: Is Celestamine* L an anti-inflammatory drug?

Official descriptions indicate the medicine works to prevent inflammation and allergy. The corticosteroid component helps modulate inflammation by suppressing the synthesis of pro-inflammatory mediators.

Q: Does taking Celestamine* L make you sensitive to the sun?

Official documentation lists 'solar sensitiveness' (photosensitivity) as a documented effect. The labeling advises taking precautions against excessive sunlight exposure while using the medicine.

Q: Can Celestamine* L cause mood changes or depression?

Officially documented serious adverse symptoms include mental disorders. These disorders can manifest as symptoms such as delusion, hallucination, or depression/excitation appearing alternately.

Q: Is Celestamine* L used for asthma symptoms?

The official indications focus on skin diseases and allergic rhinitis. While the components may be studied in related conditions, the combination product's documented primary uses are those specified in the regulatory labeling.

Q: Does Celestamine* L affect stomach issues?

Adverse reactions are documented across the gastrointestinal system. These include reports of gastric ulcer and nausea/vomiting. The official labeling also notes caution for individuals with a pre-existing peptic ulcer.

Q: Is it okay to take Celestamine* L with cold medicine?

Official warnings advise caution regarding taking any other medicinal products, including cold or flu medicines, due to the potential for interactions. Combining medicines could lead to an unwanted effect.

Q: Does Celestamine* L contain lactose or gluten?

The product labeling for the active component may include excipients like lactose monohydrate and corn starch. Specific gluten content information is defined in the full regulatory documentation.

Q: Why would a doctor switch a patient from another allergy medicine to Celestamine* L?

Official descriptions highlight that the medicine has a unique dual mechanism of action. It combines an antihistamine and a corticosteroid, which offers modulation of both allergic mediator effects and inflammatory signaling simultaneously.

Q: Can Celestamine* L affect my performance at work or school?

Potential adverse effects like drowsiness or dizziness are noted. Official warnings advise against driving a car or operating dangerous machinery, which reflects the potential for impaired performance in complex tasks.

Q: Can children use Celestamine* L?

Yes, specific dosage modifications apply to pediatric patients. The official documents state that the dosage must be adjusted by a doctor based on the child's age and symptoms, often utilizing the oral solution/syrup form for accuracy.

Q: Can older adults use Celestamine* L?

Research evidence indicates that data for older adults remain limited or insufficient in some areas. As with all populations, the dosage must be carefully determined by a healthcare professional based on the individual's age and symptoms.

Q: Is Celestamine* L suitable for long-term use?

Official guidance states that, due to the inclusion of a corticosteroid, the treatment duration is typically short-term. The majority of published research examined short-term changes, and the long-term effects of the combination are not fully established.

Q: Are there any long-term side effects to be aware of when using Celestamine* L?

Long-term effects are not fully established based on available research. However, official safety information notes that sudden discontinuation after use may cause secession symptoms (or withdrawal effects), which can include fever, headache, and muscle pain.

Q: Does Celestamine* L affect liver function?

Official guidance acknowledges that liver function is a factor for use. Specific dosage modifications may be indicated for patients with severe hepatic impairment (severe liver problems).

Q: Can people with kidney problems use Celestamine* L?

While the loratadine component is generally acceptable for patients with kidney disease, regulatory labels note that a healthcare provider should determine if a dosage adjustment is needed for individuals with impaired kidney function.

How should Celestamine* L be stored and disposed of?

How to Store and Dispose of Celestamine L (Loratadine/Betamethasone)

Official regulatory guidelines define specific conditions for storing and disposing of this medication to maintain its integrity and ensure safety.

Storage Requirements

Celestamine L must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be kept out of the sight and reach of children for safety.

It is required to store the medicine in its original package and keep the container tightly closed. The product must be protected from moisture and is explicitly directed not to be frozen. The medicine must not be used after the expiration date printed on the packaging.

Disposal Instructions

Unused or expired Celestamine L must not be disposed of via household waste or wastewater. Regulatory mandates require consulting a pharmacist for instructions on how to properly discard the medicine to ensure appropriate environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Celestamine* L found in:

A-Z Index: